000180534 001__ 180534
000180534 005__ 20241230121008.0
000180534 0247_ $$2doi$$a10.1007/s00401-022-02460-1
000180534 0247_ $$2pmid$$apmid:35771282
000180534 0247_ $$2ISSN$$a0001-6322
000180534 0247_ $$2ISSN$$a1432-0533
000180534 0247_ $$2altmetric$$aaltmetric:130528736
000180534 037__ $$aDKFZ-2022-01396
000180534 041__ $$aEnglish
000180534 082__ $$a610
000180534 1001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b0$$eFirst author$$udkfz
000180534 245__ $$aGene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.
000180534 260__ $$aHeidelberg$$bSpringer$$c2022
000180534 3367_ $$2DRIVER$$aarticle
000180534 3367_ $$2DataCite$$aOutput Types/Journal article
000180534 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1662458011_14975
000180534 3367_ $$2BibTeX$$aARTICLE
000180534 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180534 3367_ $$00$$2EndNote$$aJournal Article
000180534 500__ $$a#EA:B300#LA:B062# / 144, pages 339–352 (2022)
000180534 520__ $$aMedulloblastomas (MB) molecularly designated as Group 3 (Grp 3) MB represent a more clinically aggressive tumor variant which, as a group, displays heterogeneous molecular characteristics and disease outcomes. Reliable risk stratification of Grp 3 MB would allow for appropriate assignment of patients to aggressive treatment protocols and, vice versa, for sparing adverse effects of high-dose radio-chemotherapy in patients with standard or low-risk tumors. Here we performed RNA-based analysis on an international cohort of 179 molecularly designated Grp 3 MB treated with HIT protocols. We analyzed the clinical significance of differentially expressed genes, thereby developing optimal prognostic subdivision of this MB molecular group. We compared the transcriptome profiles of two Grp 3 MB subsets with various outcomes (76 died within the first 60 months vs. 103 survived this period) and identified 224 differentially expressed genes (DEG) between these two clinical groups (Limma R algorithm, adjusted p-value < 0.05). We selected the top six DEG overexpressed in the unfavorable cohort for further survival analysis and found that expression of all six genes strongly correlated with poor outcomes. However, only high expression of KIRREL2 was identified as an independent molecular prognostic indicator of poor patients' survival. Based on clinical and molecular patterns, four risk categories were outlined for Grp 3 MB patients: i. low-risk: M0-1/MYC non-amplified/KIRREL2 low (n = 48; 5-year OS-95%); ii. standard-risk: M0-1/MYC non-amplified/KIRREL2 high or M2-3/MYC non-amplified/KIRREL2 low (n = 65; 5-year OS-70%); iii. high-risk: M2-3/MYC non-amplified/KIRREL2 high (n = 36; 5-year OS-30%); iv. very high risk-all MYC amplified tumors (n = 30; 5-year OS-0%). Cross-validated survival models incorporating KIRREL2 expression with clinical features allowed for the reclassification of up to 50% of Grp 3 MB patients into a more appropriate risk category. Finally, KIRREL2 immunopositivity was also identified as a predictive indicator of Grp 3 MB poor survival, thus suggesting its application as a possible prognostic marker in routine clinical settings. Our results indicate that integration of KIRREL2 expression in risk stratification models may improve Grp 3 MB outcome prediction. Therefore, simple gene and/or protein expression analyses for this molecular marker could be easily adopted for Grp 3 MB prognostication and may help in assigning patients to optimal therapeutic approaches in prospective clinical trials.
000180534 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000180534 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180534 650_7 $$2Other$$aExpression
000180534 650_7 $$2Other$$aGroup 3
000180534 650_7 $$2Other$$aKIRREL2
000180534 650_7 $$2Other$$aMedulloblastoma
000180534 650_7 $$2Other$$aPrognosis
000180534 7001_ $$0P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aOkonechnikov, Konstantin$$b1$$udkfz
000180534 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b2$$udkfz
000180534 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b3$$udkfz
000180534 7001_ $$aDelaidelli, Alberto$$b4
000180534 7001_ $$aTonn, Svenja$$b5
000180534 7001_ $$aMynarek, Martin$$b6
000180534 7001_ $$0P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aSievers, Philipp$$b7$$udkfz
000180534 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b8
000180534 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b9$$udkfz
000180534 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b10$$udkfz
000180534 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b11$$udkfz
000180534 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b12$$eLast author$$udkfz
000180534 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-022-02460-1$$p339–352$$tActa neuropathologica$$v144$$x0001-6322$$y2022
000180534 8767_ $$8V10366$$92023-12-01$$d2024-12-30$$eHybrid-OA$$jZahlung erfolgt
000180534 909CO $$ooai:inrepo02.dkfz.de:180534$$pVDB$$pOpenAPC$$popenCost
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000180534 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000180534 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000180534 9141_ $$y2022
000180534 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-29$$wger
000180534 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000180534 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000180534 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000180534 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2021$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000180534 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bACTA NEUROPATHOL : 2021$$d2022-11-29
000180534 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000180534 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000180534 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000180534 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000180534 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000180534 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000180534 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x3
000180534 9200_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000180534 980__ $$ajournal
000180534 980__ $$aVDB
000180534 980__ $$aI:(DE-He78)B300-20160331
000180534 980__ $$aI:(DE-He78)HD01-20160331
000180534 980__ $$aI:(DE-He78)B062-20160331
000180534 980__ $$aI:(DE-He78)B360-20160331
000180534 980__ $$aUNRESTRICTED
000180534 980__ $$aAPC